LIFE Longevity trial: Biopsy and bacteriological examination confirm no unexpected foreign body reactions after removal of implant

08 Oct 2024 07:05 CEST

Bergen, Norway, 08 October 2024: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), can confirm no unexpected tissue or body response based on
bacteriological and biopsy tests after removal of the implanted sensor used in
first longevity study. In addition, post study testing of the sensor in-vitro
confirm intact glucose-sensitivity.

Reference is made to the press release from 11 September 2024 when the company
announced the successful completion of the first veterinary patient in the
longevity trial after 12 weeks. The sensor was removed in accordance with the
regulatory approved protocol. Lifecare's team has now completed a thorough
analysis of both the surrounding tissue and the implant, after removal.

Prior to implanting the sensor in late June, the glucose sensitivity of the
implant was tested and due to good results declared ready for the
implantation. After 12 weeks of implantation the implant was removed from the
dog.

Biopsies and bacteriological tests of tissue surrounding the sensor under
Elli's skin conducted at Norwegian University of Life Sciences (NMBU), shows
no swelling and infection in the wound post-operatively and no adverse effects
in the dog.

In-vitro functionality tests of the implant after removal have shown that the
sensor is fully glucose sensitive. The scientific team has concluded that the
implant was stable over the period of 12 weeks.

- We are especially pleased that the biopsies and bacteriological examinations
confirm the visual inspections during the removal of the implant after 12
weeks, showing no unexpected foreign body reactions. The primary goal of the
first sensor in the longevity trial was to investigate foreign body reactions
and to confirm the sensors operational lifespan in a long-term perspective.
These goals have been met in this first part of the study, says Holter.

- Retrieving the sensor from Elli has provided a valuable insight to further
understand the sensor's characteristics and helped identify potential areas
for improvement. We are also very pleased to report that biopsy tests show no
signs of adverse effects in our first patient of our longevity trial, says Jo
Amundstad at Lifecare Veterinary.

Lifecare plan to initiate the next phase of testing in the upcoming weeks, the
initiation is subject to internal quality control of produced sensors and
bacteriological tests prior to implantation.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

629187_LIFE Longevity trial- Biopsy and bacteriological examination confirm no unexpected foreign body reactions after removal of implant.pdf